ASP
TXG icon

Adams Street Partners’s 10x Genomics TXG Stock Holding History

Adams Street Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,340
Closed -$756K – 28
2020
Q4 		$756K Buy
+5,340
New +$775K 0.16% 14

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Adams Street Partners's TXG Position: Q1 2021 in Review

Adams Street Partners sold out of 10x Genomics (TXG) in Q1 2021, closing a stake of 5,340 shares — an estimated $756K sold.

Adams Street Partners first reported a position in TXG in Q4 2020 and held it in 1 quarter. The position peaked at $756K in Q4 2020. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

  • Adams Street Partners reported no remaining 10x Genomics position as of Q1 2021 after selling out during the quarter.
  • Adams Street Partners sold 5,340 10x Genomics shares in Q1 2021, an estimated $756K.
  • Adams Street Partners first reported a position in 10x Genomics in Q4 2020 and held it in 1 quarter.
  • Adams Street Partners's 10x Genomics position peaked at $756K in Q4 2020.
  • 324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Adams Street Partners's 13F filing for Q1 2021, filed 10 May 2021.